-Norwegian Cellcura delivers prototype solution to US MGH.
NORDIC BUSINESS REPORT-June 15, 2011--Norwegian Cellcura delivers prototype solution to US MGH(C)2011 M2 COMMUNICATIONS http://www.m2.com
15 June 2011 - Norwegian biotechnology company Cellcura ASA (OSL: CELL) said today it has supplied the first prototype of a stem-cell laboratory solution for testing and assessment to the Massachusetts General Hospital (MGH) in Boston, USA.
The solution was developed in close cooperation with MGH and is designed to meet the needs of stem-cell research laboratories.
MGH signed a collaboration agreement with Cellcura's US arm in December 2010, to reflect Cellcura's engagement in the development of novel assisted reproduction therapies (ART) and stem-cell medical equipment. MGH thus aims to expand its expertise and patient-care capabilities.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||Nordic Business Report|
|Date:||Jun 15, 2011|
|Previous Article:||-Bavarian Nordic announces deals to supply smallpox vaccine.|
|Next Article:||-Norwegian oil output declines in May 2011.|